학술논문

CLINICAL AND PHARMACODYNAMIC BIOMARKER RESULTS FROM PORTER, A MULTI-COHORT PHASE 1 PLATFORM TRIAL OF COMBINATION IMMUNOTHERAPY FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS